Health & Fitness
Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Mon, October 11, 2010Sun, October 10, 2010Sat, October 9, 2010Fri, October 8, 2010Thu, October 7, 2010Wed, October 6, 2010Tue, October 5, 2010BioCryst Pharmaceuticals to Announce Third Quarter 2010 Financial Results on October 28, 2010
Published in Health and Fitness on Monday, October 18th 2010 at 4:05 GMT by Market Wire
RESEARCH TRIANGLE PARK, N.C.--([ BUSINESS WIRE ])--BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its third quarter 2010 financial results will be released on Thursday, October 28, 2010. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Companya™s programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.
The Web cast can be accessed by logging onto [ www.biocryst.com ]. Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-877-303-8027 (United States) or 1-760-536-5165 (International). No passcode is needed for the call. The audio portion of the Web cast will be archived and available for replay for at least 14 days.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor forhematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's Web site at [ www.biocryst.com ].
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at [ http://investor.shareholder.com/biocryst/sec.cfm ].
BCRXW
